Company
At Chiasma, we utilize our proprietary TPE system to transform injectable drugs into oral drugs with the same or with new indications. We have a pipeline of drug candidates in development that potentially improve patient convenience, provide better clinical outcomes or improve the cost of care. Our focus is on breakthrough products for the orphan drug community. More… |
OctreolinTM
Octreolin is an oral octreotide acetate in clinical development for patients with acromegaly, a hormonal disorder that results from an excess of growth hormone. Today octreotide is typically administered by large bore intra-muscular needle injections. Our oral octreotide has the potential to improve the quality of life of acromegaly patients. A Phase 3 study began in Q4 2011. More… |
Patients
At Chiasma, we recognize the challenges of living with a chronic disease. We are focused on developing Octreolin, an investigational oral octreotide therapy. This is the only oral somatostatin analog treatment for acromegaly currently in clinical development. For more information about Octreolin or how to enroll to our Phase 3 clinical study please click here. More… |
